Induction immunosuppression in high-risk kidney transplant recipients; beauty and the beast

Keyphrases

• High Risk 100%
• Acute Rejection 100%
• Induction Immunosuppression 100%
• Kidney Transplant Recipients 100%
• Immunosuppression 66%
• Kidney Transplant 66%
• High-risk Recipient 66%
• Scientific Community 33%
• Standard of Care 33%
• Monoclonal Antibody 33%
• Low Incidence 33%
• Patient Outcomes 33%
• Graft Outcome 33%
• Antithymocyte Globulin 33%
• Alemtuzumab 33%
• Transplant Center 33%
• Muromonab-CD3 33%
• Rituximab 33%
• Polyclonal Antibody 33%
• Bortezomib 33%
• Emerging Agents 33%
• Eculizumab 33%
• Renal Replacement Therapy 33%
• End-stage Kidney Disease 33%
• Induction Agents 33%

Medicine and Dentistry

• Eculizumab 25%

Immunology and Microbiology

• Allotransplantation 20%